Suppr超能文献

抗癌药物引起的严重皮肤不良反应:抗癌靶向治疗或免疫治疗相关风险的最新综述。

Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

机构信息

Department of Dermatology, College of Medicine, Chang Gung Memorial Hospital, Keelung, Linkou, Taipei, Taiwan.

Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan.

出版信息

J Immunol Res. 2018 Jan 17;2018:5376476. doi: 10.1155/2018/5376476. eCollection 2018.

Abstract

Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. Anticancer drugs, including chemotherapy, target therapy, and recent immunotherapy causing skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) with increase morbidity and mortality while they are receiving cancer treatments, have been proposed to be a result of direct skin toxicity or drug hypersensitivity reactions (these are proposed mechanism, not definite). Differentiating SCARs from other more commonly seen reactions with a better outcome help prevent discontinuation of therapy and inappropriate use of systemic immunosuppressants for presumable allergic reactions, of which will affect the clinical outcome. In this article, we have reviewed published articles from 1950 to August 2017 for SJS/TEN associated with anticancer drugs, including chemotherapy, targeted therapy, and immunotherapy. We aimed to provide an overview of SJS/TEN associated with anticancer drugs to increase clinician recognition and accelerate future studies on the pathomechanism and managements.

摘要

皮肤不良反应在接受抗癌药物治疗的患者中很常见。抗癌药物,包括化疗、靶向治疗和最近的免疫治疗,可导致皮肤反应,从轻度皮疹到危及生命的严重皮肤不良反应(SCAR),如史蒂文斯-约翰逊综合征(SJS)和中毒性表皮坏死松解症(TEN),这些不良反应会增加发病率和死亡率,同时也会影响癌症治疗。人们认为这些不良反应是直接皮肤毒性或药物过敏反应的结果(这些是提出的机制,不是确定的)。区分 SCAR 与其他更常见的、预后较好的反应有助于预防因推测的过敏反应而停止治疗和不恰当地使用全身性免疫抑制剂,这会影响临床结果。本文综述了 1950 年至 2017 年 8 月发表的与抗癌药物(包括化疗、靶向治疗和免疫治疗)相关的 SJS/TEN 相关文章。旨在概述与抗癌药物相关的 SJS/TEN,以提高临床医生的认识,并加速对发病机制和管理的未来研究。

相似文献

2
Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.
Cancer Manag Res. 2018 May 17;10:1259-1273. doi: 10.2147/CMAR.S163391. eCollection 2018.
3
Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
J Allergy Clin Immunol Pract. 2017 May-Jun;5(3):757-763. doi: 10.1016/j.jaip.2017.02.013. Epub 2017 Mar 27.
4
Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data.
Oncologist. 2019 Feb;24(2):266-272. doi: 10.1634/theoncologist.2017-0511. Epub 2018 Sep 25.
5
Cutaneous manifestations of nontargeted and targeted chemotherapies.
Semin Oncol. 2016 Jun;43(3):419-25. doi: 10.1053/j.seminoncol.2016.02.018. Epub 2016 Feb 23.
7
Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions.
J Immunol Res. 2017;2017:6928363. doi: 10.1155/2017/6928363. Epub 2017 Oct 31.
8
Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
J Dermatol Sci. 2012 Jun;66(3):190-6. doi: 10.1016/j.jdermsci.2012.04.002. Epub 2012 Apr 11.
10
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Am J Clin Dermatol. 2018 Nov;19(Suppl 1):31-39. doi: 10.1007/s40257-018-0384-3.

引用本文的文献

2
Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations.
NPJ Precis Oncol. 2024 Nov 21;8(1):271. doi: 10.1038/s41698-024-00758-9.
3
The Cellular Stress and Cutaneous Manifestations in Renal Cell Carcinomas-A Narrative Review.
J Clin Med. 2024 Jun 21;13(13):3640. doi: 10.3390/jcm13133640.
4
Causes and Management of Cutaneous Adverse Drug Reactions: A Comprehensive Review.
Cureus. 2024 Mar 1;16(3):e55318. doi: 10.7759/cureus.55318. eCollection 2024 Mar.
5
Anticancer therapy-induced adverse drug reactions in children and preventive and control measures.
Front Pharmacol. 2024 Feb 15;15:1329220. doi: 10.3389/fphar.2024.1329220. eCollection 2024.
6
A Compilation of Drug Etiologies of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Cureus. 2023 Nov 13;15(11):e48728. doi: 10.7759/cureus.48728. eCollection 2023 Nov.

本文引用的文献

1
Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.
Eur J Dermatol. 2017 Jun 1;27(3):266-270. doi: 10.1684/ejd.2017.3023.
2
Methotrexate-induced epidermal necrosis: A case series of 24 patients.
J Am Acad Dermatol. 2017 Aug;77(2):247-255.e2. doi: 10.1016/j.jaad.2017.02.021. Epub 2017 May 10.
3
Severe cutaneous adverse reactions to drugs.
Lancet. 2017 Oct 28;390(10106):1996-2011. doi: 10.1016/S0140-6736(16)30378-6. Epub 2017 May 2.
4
Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients.
Eur J Cancer. 2017 Aug;81:237-239. doi: 10.1016/j.ejca.2017.03.026. Epub 2017 Apr 21.
5
Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.
J Cutan Pathol. 2017 Apr;44(4):381-384. doi: 10.1111/cup.12876. Epub 2017 Jan 23.
6
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma.
Oncoimmunology. 2016 Aug 19;5(9):e1214788. doi: 10.1080/2162402X.2016.1214788. eCollection 2016.
7
Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib.
Eur J Dermatol. 2016 Aug 1;26(4):413-4. doi: 10.1684/ejd.2016.2807.
8
Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.
Lung Cancer. 2016 May;95:35-8. doi: 10.1016/j.lungcan.2016.02.015. Epub 2016 Mar 2.
9
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy.
Clin Cancer Res. 2016 Aug 15;22(16):4023-9. doi: 10.1158/1078-0432.CCR-15-2872. Epub 2016 Mar 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验